about us
Here’s the deal. We’re all about helping biologics and gene therapy researchers break free from tools that just don’t cut it. Unleashing problem-tackling solutions that make a huge difference in the real science they do every day. That’s our mantra, our promise and we own it.
Vision
Be the go-to biologics and gene therapy tools supplier.
Path
Uncover big scientific problems. Solve them. Period.
People
The right group of people can accomplish anything.
products
Science is no joke. That’s why we uncaged the right tools for the job. Ones that make a big-time difference in getting it done. Products that prepare, process and characterize even the most unruly samples and totally crank up your research.
events
news
-
Unchained Labs goes all in on Lipid Nanoparticles, acquires Blacktrace Holdings!
July 17, 2023 – Pleasanton, CA – Unchained Labs, the life sciences company that’s all about getting biologics and gene therapy researchers the right tools for the job, acquired Blacktrace Holdings today. For decades, Blacktrace’s Dolomite microfluidics have been helping scientists with complex workflows. More recently, their Particle Works solutions are changing the game on…
-
Unchained Labs goes viral again with new adenovirus quant application on Stunner!
February 7, 2023 – Pleasanton, CA – Unchained Labs, the life sciences company that’s all about getting biologics and gene therapy researchers the right tool for the job, launched its new adenovirus quantification application on Stunner today. Stunner can already measure titer and empty/full ratio for AAVs, and now it can do the same for…
-
Unchained Labs finds the Lenti Leprechaun at the end of the rainbow
January 17, 2023 – Pleasanton, CA – Unchained Labs, the life sciences company that’s all about getting biologics and gene therapy researchers the right tool for the job, launched Leprechaun today – the first platform to simultaneously measure lentivirus titer and structure at any step in the development process – no matter how crude or…
-
Unchained Labs adds new AAV and LNP focused consumables to the Unagi menu!
September 21, 2022 – Pleasanton, CA – Unchained Labs, the life sciences company that’s all about getting researchers the right tool for the job, launched two new molecular weight cutoff consumables for Unagi today. Unagi is the only completely hands-free benchtop buffer exchange platform for biologics and gene therapies – and now it’s even better…
-
Unchained Labs locks down forever home with new Pleasanton campus
August 3, 2022 – Pleasanton, CA – Unchained Labs, the life sciences company that’s all about getting biologics and gene therapy researchers the right tool for the job will build a new, expanded campus right around the corner from its current headquarters in Pleasanton, CA. Unchained entered into a very long-term (basically forever) lease on…
Need more?
our tribe
jobs
Unchained people get amazing amounts of work done, focus on what matters and never give up. They thrive on mind-blowing results and make decisions with incomplete information on a daily basis. They’re team players that always know it’s all about we, not I.
board
Dr. Martin Madaus
Operating Executive, The Carlyle Group
Dr. Martin D. Madaus is a serial global healthcare CEO, board member, investor and strategy consultant with 30 years of experience in biotech, medical devices, in vitro diagnostics and life sciences tools. He has a track record for delivering outstanding results by transforming large and complex businesses. He currently works for The Carlyle Group as an Operating Executive and serves as Chairman of Ultivue, Inc., Emulate Bio, Lead Director at Quanterix Corporation (QTRX) and Director at Candela Medical.
He was Chairman and Chief Executive Officer at Ortho-Clinical Diagnostics, Inc. (NASDAQ:OCDX) from June 2015 until February of 2019 leading the carve-out from J&J and the business turnaround. Prior to joining Ortho, Dr. Madaus served as Executive Chairman of Quanterix Corporation, and as Senior Healthcare Advisor to The Carlyle Group. He was Chairman, President and Chief Executive Officer of Millipore Corporation (NYSE: MIL) from January 2005 to July 2010. In addition, Dr. Madaus was President and Chief Executive Officer of Roche Diagnostics Corporation North America from 2000 to 2004. Prior to that, he served as Vice President of Business Development for Roche Molecular Diagnostics, and served as the President of Roche Diagnostics Canada.
Dr. Madaus started his career in 1989 at Boehringer Mannheim, Germany and served in various product management, marketing and general management roles in Germany, the United States and Canada. Dr. Madaus has extensive public and private company board experience and has served on the board of Mettler-Toledo International Inc. (NYSE: MTD), Covidien PLC (NYSE: COV), Millipore (NYSE:MIL), PPD Inc. (NASDAQ:PPD), Quanterix (NASDAQ: QTRX), Candela Medical, Ultivue Inc. and Emulate Bio.
Dr. Madaus received a Doctor of Veterinary Medicine degree from the University of Munich in Germany and a PhD in Veterinary Medicine from the Veterinary School of Hanover in Germany.
Robert Schmidt
Managing Director, The Carlyle Group
Robert R. Schmidt is a Managing Director on the U.S. Buyout team at The Carlyle Group, focused on private equity investments in the healthcare sector. He is based in New York. Since joining Carlyle in 2011, Mr. Schmidt has been involved in a number of the firm’s investments globally, including Beats Electronics, Grand Rounds, MedRisk, One Medical, Ortho Clinical Diagnostics, Sedgwick and Unchained Labs. He is currently a member of the Board of Directors of Grand Rounds, MedRisk, One Medical, Ortho Clinical Diagnostics, and Unchained Labs.
Prior to joining Carlyle, Mr. Schmidt worked at Welsh, Carson, Anderson & Stowe, a private equity firm focused on healthcare and technology investments, and Merrill Lynch Global Private Equity, focused on buyouts in North America.
Mr. Schmidt received his M.B.A. from Harvard Business School and a B.S. in economics from The Wharton School at the University of Pennsylvania, where he is currently a member of the External Advisory Board at the Leonard Davis Institute of Health Economics.
Samuel Tang
Senior Associate, The Carlyle Group
Samuel Tang is a Senior Associate on the U.S. Buyout team at The Carlyle Group, focused on private equity investments in healthcare, and is based in New York.
Prior to joining Carlyle in 2015, Sam worked in the healthcare investment banking group at J.P. Morgan. Sam holds an M.B.A. from The Wharton School of the University of Pennsylvania, a J.D. from the University of Pennsylvania Carey Law School, and an A.B. summa cum laude from Princeton University.
LAURA J. HAMILL
Biotech Executive
Laura J. Hamill has deep experience in the biopharmaceutical industry, with over 30 years of global commercial experience in a variety of executive leadership positions. Most recently, she served as Executive Vice President, Worldwide Commercial Operations, for Gilead Sciences, Inc., where she was accountable for 2,200 employees and $22 billion in annual revenue and led the global commercial strategic direction and long-term planning.
Over an 18-year career at Amgen, Laura held a number of executive roles in the United States and internationally. In her last role as Senior Vice President and General Manager of the US, she was responsible for $18 billion in annual revenue and managed a team of 2,000 employees across all of Amgen’s therapeutic areas. She also served as the Chairperson of Amgen’s Senior Women’s Leadership Council.
Ms. Hamill is currently a member of the Board of Directors for, Pardes Biosciences, BB Biotech, Y-mAbs Therapeutics and AnaptysBio. She also is a board member for two private companies, Unchained Labs and Scilex Pharmaceuticals. Ms. Hamill holds a bachelor’s degree in business administration from the University of Arizona.
meme-a-palooza
get in touch
Have a question or can’t wait to find out more?
"…they'll never take our FREEDOM!"
- WILLIAM WALLACE, BRAVEHEART